Back to Agenda
Poster Session and Networking Reception
Speaker(s)
Nancy Griffith, PHD
, Wave Life Sciences, United States
The Effects of Chiral Control on the Pharmacologic Properties of Antisense Oligonucleotides
Joe Harford, PHD
President & CEO, SynerGene Therapeutics, Inc., United States
A Targeted Nanocomplex that Actively Ferries Therapeutic Nucleic Acids Across the Blood-Brain Barrier
Zhong Zhong
Vice President, Biology, Wave Life Sciences, United States
DMD Exon 51 Skipping Efficiency and Dystrophin Protein Restoration Induced by WVE-210201: An Investigational Stereopure ASO
Petra Kos, PHD, MPHARM
Postdoctoral Fellow, UT Southwestern Medical Center, United States
miRNA-Loaded Lipid Nanoparticles for Ovarian Cancer Treatment
Meena Meena, PHD
Senior Director, Wave Life Sciences, United States
Preclinical Studies of WVE-120101 and WVE-12010: Investigational Stereopure ASOs for Huntington’s Disease (HD)
Hong Jiang, MS
Scientist I, Leal Therapeutics, United States
Impurity and Failure sequence Profile Change Due to Omission of the Capping Step in Synthesis of PS/PO Mixed Backbone ASOs
Silke Klick, PHD
Regulatory Director CMC, AstraZeneca, Sweden
Quality Aspects of mRNA Drug Products: How Do We Control Identity, Purity, and Potency?
Ruiting Liang, PHD
Senior Scientist, Alkermes, United States
A Control Strategy for GMP Manufacturing of Antisense Oligonucleotides Based on a Liquid DS Platform
Jennifer Freedman, PHD
Assistant Professor, Duke Cancer Institute, United States
Development of a Novel Therapeutic Splice-Switching Oligonucleotide Targeting Race-Related Aggressive Prostate Cancer
Corrie L Gallant-Behm, PHD
Research Scientist III, Miragen Therapeutics, Inc., United States
Translatability of miR-29 PD Biomarkers from Preclinical Models to Mechanistic Proof of Concept in an MRG-201 Clinical Trial
Marcin Kortylewski, PHD, MS
Professor, City Of Hope, Beckman Research Institute, United States
Dual Function Oligonucleotide CpG-STAT3 Inhibitor for B-Cell Lymphoma Immunotherapy
Mai Bailey Thayer, MS
Senior Associate Scientist, Amgen Inc., United States
Ultra-Sensitive Locked Nucleic Acid Hybridization-Ligation ECL ELISA for Quantitative Measurement of siRNA
Girish R Chopda, PHD
Associate Director, Nonclinical Development, Dicerna Pharmaceuticals, United States
Comparison of Subcutaneous and Intravenous Routes of Administration for Liver-Targeted RNAi Agents: Effect of PK-Modulating
Josh Whisenand
, TriLink BioTechnologies, United States
Innate Immune Focused Approaches to Maximize Messenger RNA Therapeutic Activity
Brent Allen Dickinson
Manager, Pharmacokinetics, Miragen Therapeutics, United States
Pharmacokinetic and Safety Data in Monkey and Human After IV Bolus Administration of MRG-106: An Inhibitor of miR-155
Anita G Seto, PHD
Associate Director, Translational Sciences, miRagen Therapeutics, United States
Phase 1 Trial Evaluating MRG-106: A Synthetic Inhibitor of microRNA-155 in CTCL Patients
Have an account?